PD-L1 expression in papillary renal cell carcinoma

Takanobu Motoshima, Yoshihiro Komohara, Chaoya Ma, Arni Kusuma Dewi, Hirotsugu Noguchi, Sohsuke Yamada, Toshiyuki Nakayama, Shohei Kitada, Yoshiaki Kawano, Wataru Takahashi, Masaaki Sugimoto, Motohiro Takeya, Naohiro Fujimoto, Yoshinao Oda, Masatoshi Eto

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The immune escape or tolerance of cancer cells is considered to be closely involved in cancer progression. Programmed death-1 (PD-1) is an inhibitory receptor expressed on activating T cells, and several types of cancer cells were found to express PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2). Methods: In the present study, we investigated PD-L1/2 expression in papillary renal cell carcinoma (pRCC). Result: We found PD-L1 expression in 29 of 102 cases, but no PD-L2 expression was seen. PD-L1 expression was not significantly correlated with any clinicopathological factor, including progression-free survival and overall survival. The frequency of PD-L1-positive cases was higher in type 2 (36%) than in type 1 (22%) pRCC; however, there was no significant difference in the percentages of score 0 cases (p value = 0.084 in Chi-square test). The frequency of high PD-L1 expression cases was higher in type 2 (23%) than in type 1 (11%), and the frequency of high PD-L1 expression cases was higher in grade 3/4 (21%) than in grade 1/2 (13%). However, no significant association was found between PD-L1 expression and all clinicopathological factors in pRCC. Conclusion: High expression of PD-L1 in cancer cells was potentially associated to highly histological grade of malignancy in pRCC. The evaluation of the PD-L1 protein might still be useful for predicting the efficacy of anti-cancer immunotherapy using immuno-checkpoint inhibitors, however, not be useful for predicting the clinical prognosis.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBMC Urology
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 13 2017

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Urology

Fingerprint Dive into the research topics of 'PD-L1 expression in papillary renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Motoshima, T., Komohara, Y., Ma, C., Dewi, A. K., Noguchi, H., Yamada, S., Nakayama, T., Kitada, S., Kawano, Y., Takahashi, W., Sugimoto, M., Takeya, M., Fujimoto, N., Oda, Y., & Eto, M. (2017). PD-L1 expression in papillary renal cell carcinoma. BMC Urology, 17(1), 1-6. https://doi.org/10.1186/s12894-016-0195-x